Abstract
1. The fate of bumetanide was studied in four healthy volunteers both after intravenous oral administration of [14C]-bumetanide (0.5 mg). 2. The absorption of oral [14C]-bumetanide was rapid (absorption half-life 0.61 h) and complete with a urinary recovery of about 80% of the intravenous or oral dose during 48 h. 3. The elimination of [14C]-bumetanide was rapid with a half-life of elimination (T 1/2 beta) of 1.5 h. 4. Protein bound fraction of [14C]-bumetanide in plasma was 95%. No bumetanide was found in red blood cells. 5. Four metabolites of [14C]-bumetanide were found in urine. Together they accounted for about one third of the radio-activity excreted into urine during the first 6 h after the administration of the drug. 6. Bumetanide is rapidly and completely absorbed from the gastrointestinal tract, bound extensively to plasma proteins, metabolized to some extent and excreted rapidly, principally into urine.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Asbury M. J., Gatenby P. B., O'Sullivan S., Bourke E. Bumetanide: potent new "loop" diuretic. Br Med J. 1972 Jan 22;1(5794):211–213. doi: 10.1136/bmj.1.5794.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Davies D. L., Lant A. F., Millard N. R., Smith A. J., Ward J. W., Wilson G. M. Renal action, therapeutic use, and pharmacokinetics of the diuretic bumetanide. Clin Pharmacol Ther. 1974 Feb;15(2):141–155. doi: 10.1002/cpt1974152141. [DOI] [PubMed] [Google Scholar]
- Feit P. W., Roholt K., Sorensen H. GLC determination and urinary recovery of bumetanide in healthy volunteers. J Pharm Sci. 1973 Mar;62(3):375–379. doi: 10.1002/jps.2600620304. [DOI] [PubMed] [Google Scholar]
- Halladay S. C., Carter D. E., Sipes I. G., Brodie B. B., Bressler R. Evidence for the metabolism of bumetanide in man. Life Sci. 1975 Sep 15;17(6):1003–1009. doi: 10.1016/0024-3205(75)90455-5. [DOI] [PubMed] [Google Scholar]
- Kelly M. R., Cutler R. E., Forrey A. W., Kimpel B. M. Pharmacokinetics of orally administered furosemide. Clin Pharmacol Ther. 1974 Feb;15(2):178–186. [PubMed] [Google Scholar]
- Loo J. C., Riegelman S. New method for calculating the intrinsic absorption rate of drugs. J Pharm Sci. 1968 Jun;57(6):918–928. doi: 10.1002/jps.2600570602. [DOI] [PubMed] [Google Scholar]
- Magnussen M. P., Eilertsen E. Proceedings: Species differences in the diuretic activity and metabolism of bumetanide. Naunyn Schmiedebergs Arch Pharmacol. 1974;282(Suppl):suppl 282–282:R61. [PubMed] [Google Scholar]
- Olesen K. H., Sigurd B., Steiness E., Leth A. Bumetanide, a new potent diuretic. A clinical evaluation in congestive heart failure. Acta Med Scand. 1973 Jan-Feb;193(1-2):119–131. [PubMed] [Google Scholar]
- Ostergaard E. H., Magnussen M. P., Nielsen C. K., Eilertsen E., Frey H. H. Pharmacological properties of 3-n-butylamino-4-phenoxy-5-sulfamylbenzoic acid (Bumetanide), a new potent diuretic. Arzneimittelforschung. 1972 Jan;22(1):66–72. [PubMed] [Google Scholar]
- Walker S. R. The influence of protein binding on the excretion of some sulphanilamidopyrimidines in man. J Pharm Pharmacol. 1970 Aug;22(8):574–577. doi: 10.1111/j.2042-7158.1970.tb10573.x. [DOI] [PubMed] [Google Scholar]